An Open-label, Prospective, Multicentre, Phase I/II Dose Escalation Study to Determine the Maximum Tolerated Dose and to Assess the Safety and Efficacy of P1101, PEG-Proline-Interferon Alpha-2b in Patients With Polycythaemia Vera

Trial Profile

An Open-label, Prospective, Multicentre, Phase I/II Dose Escalation Study to Determine the Maximum Tolerated Dose and to Assess the Safety and Efficacy of P1101, PEG-Proline-Interferon Alpha-2b in Patients With Polycythaemia Vera

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Ropeginterferon alfa-2b (Primary)
  • Indications Polycythaemia vera
  • Focus Adverse reactions
  • Acronyms PEGINVERA
  • Sponsors AOP Orphan Pharmaceuticals AG
  • Most Recent Events

    • 25 Jun 2017 Updated results (n=29) presented at the 22nd Congress of the European Haematology Association.
    • 25 Jun 2017 Results published in an AOP Orphan Pharmaceuticals AG media release.
    • 25 Jun 2017 According to an AOP Orphan Pharmaceuticals AG media release, latest results from the study were presented at the 22nd Congress of the European Hematology Association (EHA) 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top